Locus Biosciences has built the world’s most powerful platform to selectively remove pathogenic bacterial species from the human body while leaving the many species of “good” bacteria in the microbiome unaffected. Our products can also exploit bacteria in the microbiome to produce therapeutics that may be beneficial in treating a variety of diseases.
We are developing products targeting four bacterial species that cause millions of antibiotic resistant infections and hundreds of thousands of deaths worldwide each year. We are also researching new ways to address unmet medical needs in Inflammatory Bowel Disease (IBD) and other microbiome-related diseases.
E. coli infections
P. aeruginosa infections
S. aureus infections
K. pneumoniae infections
Inflammatory Bowel Disease
LBP-EC01 is a precision medicine designed to target E. coli infections. It is a cocktail of bacteriophages engineered to precisely remove E. coli bacteria in patients with urinary tract infections (UTIs).
Worldwide, an estimated 150 million people are affected by UTIs each year. Approximately 80 percent of these are caused by E. coli, often including difficult-to-treat strains that are resistant to commonly used antibiotics. Nearly 40 percent of patients with UTIs experience a recurrence within months of the first episode. Both the U.S. Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) have identified antibiotic-resistant E. coli as an urgent and serious public health threat requiring development of new treatments.
Locus is currently enrolling patients in the ELIMINATE trial, a landmark registration-enabling Phase 2/3 trial testing LBP-EC01 in acute uncomplicated UTIs caused by MDR E. coli.
More about ELIMINATE trial
Locus has partnered with Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS) to develop LBP-EC01. Up to $77 million provided by BARDA will help advance clinical development of LBP-EC01 through late stage clinical development and the marketing authorization process defined by the U.S. Food and Drug Administration (FDA).
LBP-PA01 is a precision therapeutic designed to target P. aeruginosa infections. Locus partnered with Janssen Pharmaceuticals to develop this product.
LBP-SA01 is a precision therapeutic designed to target S. aureus infections. Locus partnered with Janssen Pharmaceuticals to develop this product.
LBP-KP01 is a precision therapeutic designed to target K. pneumoniae infections. Locus has partnered with the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to develop this product.
Locus Biosciences is developing multiple approaches leveraging its Locus Biopharmaceutical Development platform to address both the pathogens and the resulting damage associated with Inflammatory Bowel Disease.